|
Author | Year | Specimens | Comparison | Methodology | Proteins of interest |
|
Bernard et al. [12] | 2003 | Cell lines | Melanocyte versus melanoma (primary and metastatic) | 2DE and mass spectrometry | Nucleophosmin/B23, HDGF, CTSD |
Sinha et al. [14] | 2003 | Cell lines | Responsive to chemotherapy versus nonresponsive | 2DE and MALDI-TOF | Multiple (25) |
Wilson et al. [28] | 2004 | Serum | Stage I or II melanoma patients, recurrence versus none | SELDI-TOF | n/a (expression profiles) |
Carta et al. [13] | 2005 | Cell lines | Primary versus metastatic melanoma | 2DE and mass spectrometry | HSP27, HSP60, HSPA8, PRDX2 |
Mian et al. [29, 30] |
2005 | Serum | Stage I melanoma versus Stage IV melanoma | SELDI-TOF | n/a (expression profiles), further work identified SAA |
Mian et al. [29, 30] |
2005 | Serum | Stage III melanoma patients, recurrence versus none | SELDI-TOF |
Takikawa et al. [24] | 2009 | Serum | Volunteers versus melanoma patients | Nano LC and MALDI-TOF | PPBP |
Caron et al. [27] | 2009 | Serum | Volunteers versus melanoma patients | SELDI-TOF | n/a (expression profiles) |
Greco et al. [31] | 2009 | Serum | Patients undergoing biopsy, melanoma versus not | 2DE and MALDI-TOF | TTR, AGT, DBP |
Paulitschke et al. [46] | 2009 | Secreted proteins from and cell lines and skin samples | Normal skin versus Melanoma | Nano LC and mass spectrometry | GPX5, periostin, stanniocalcini-1 |
Suzuki et al. [36] | 2010 | Serum | Volunteers versus melanoma patients | Autoantibody detection | EEF2, ENO1, ALDOA, GAPDH, HNRNP-A2B1 |
Hood et al. [47] | 2010 | Cell lines | Melanoma versus normal skin | Nano LC and mass spectrometry | Tenascin-C, fibronectin, ACN4, TSP-1 |
Liu et al. [37] | 2010 | Serum | Node negative versus node positive melanoma patients | Autoantibody detection | GRP94, ASAH1, CTSD, LDHB |
Hardesty et al. [16] | 2011 | Surgically resected lymph nodes | Recurrence versus no recurrence | MALDI-IMS | Cytochrome C calmodulin |
|